Positron-emission tomography and assessment of cancer therapy.
about
A computational pipeline for quantification of pulmonary infections in small animal models using serial PET-CT imagingStable isotope-resolved metabolomics and applications for drug developmentMetabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsPositron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response MonitoringNanoparticle-facilitated functional and molecular imaging for the early detection of cancerMolecular imaging for cancer diagnosis and surgery.State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PETAssessment of PET/CT in multifocal myeloid sarcomas with loss of TET2: a case report and literature reviewAnimal models of osteoarthritis: classification, update, and measurement of outcomesPrognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysisOptimisation of whole-body PET/CT scanning protocolsEarly prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral textureNovel molecular and nanosensors for in vivo sensingMulticenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With LymphomaA systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?Associations between cancer-related information seeking and receiving PET imaging for routine cancer surveillance--an analysis of longitudinal survey data.Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.Thoracic and abdominal organ uptake of 2-deoxy-2-[18F]fluoro-D-glucose (18FDG) with positron emission tomography in the normal dog.Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer.Early treatment response monitoring using 2-deoxy-2-[ 18F]fluoro-D-glucose positron emission tomography imaging during fractionated radiotherapy of head neck cancer xenografts.Diffusion-weighted MRI for staging and evaluation of response in diffuse large B-cell lymphoma: a pilot study.FDG-PET Scan: a new Paradigm for Follicular Lymphoma ManagementSimultaneous Tumor Segmentation, Image Restoration, and Blur Kernel Estimation in PET Using Multiple RegularizationsFDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumorsPET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis.Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CTAdaptive region-growing with maximum curvature strategy for tumor segmentation in 18F-FDG PET.Limited Identification of Dual-time-point Positron Emission Tomography/Computed Tomography in Advanced Colorectal NeoplasmsA New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions.Correlation between fluorodeoxyglucose positron emission tomography and magnetic resonance imaging findings of non-suppurative meningoencephalitis in 5 dogsHyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumorsInstrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.Assessment of early tumor response to cytotoxic chemotherapy with dynamic contrast-enhanced ultrasound in human breast cancer xenografts.DOI-based reconstruction algorithms for a compact breast PET scanner.Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis.Metabolic positron emission tomography imaging in cancer detection and therapy response.
P2860
Q22001019-78F8E6A8-C88A-4BE6-BA3A-54EA69C85674Q24629149-92B90EF7-F1A3-42E1-85BD-5C570F3C0A83Q26740567-E864B687-0EBF-4A27-B987-8BEB9F8A0B8AQ26765882-3C17B1F9-1002-427D-B068-B2838AD0981CQ26828849-A0E01730-3497-48D2-83D7-5C74581B0BB9Q27687291-373E8F1F-1A5F-42CC-91DE-C45A2D59AEBCQ27694674-7AD19E38-5E06-4B7B-BB6F-112E30622768Q28069893-4CB1C32C-0888-4AF4-B6F5-F00B6DE34D77Q28072990-5F99A8C8-A9AC-42BE-93D8-2089D0F556F1Q28081159-0F3B0152-40AB-437A-98D7-FB421D3CBB61Q28744472-BC80102B-7F4B-4EE6-85C0-E56188DDB225Q30433481-FA342E88-5321-458A-8708-AC72CA1ED815Q30450856-00A715B5-3432-4E4D-BB3A-1DAFBF87F97AQ30491972-26F117FC-2CA4-489F-B40A-3A94D8EC0637Q30497087-9F7B337A-BCC9-4C38-895C-2B6A3CE5A65CQ30759702-2C87B6AF-BFBA-47FF-B46E-86CEAA379937Q31014798-E1A4E529-EB5B-479B-AF5F-98F1C3EBA533Q33328879-8D76CA1F-DE06-4595-9DB6-8DA665D6CBDCQ33341466-C1B95367-C69D-4A5E-98CF-244CBAEF5ED2Q33395114-6F1F77DB-51A9-4B64-B4E1-84243D900080Q33616723-B994CD78-74E9-4A3E-A8E2-C278DF8371A2Q33631226-F1186528-E19B-4AEA-B9C4-55A302648AE7Q33642244-EF3A18B5-52D7-415A-9AE4-10C37296D1FFQ33777233-C8FF2476-4711-4D72-8633-6A9FEDF142CFQ33797361-61ED8CB2-7F60-43B6-B825-B5E5A9DB829AQ33806271-8881A58A-9EC0-446B-860E-86530DCB78C1Q33814606-B505A414-BBE0-44D0-9747-FE1FE8B0122EQ33833615-396B93FC-F0D1-424C-AA2D-4811146277D1Q33840367-2D007A1D-E03E-4802-AC81-BB7ABCF40DD4Q33873255-B6BA583A-B309-4CC0-967D-C412516FAF3DQ33874655-46FE9481-B68E-46DC-ABA7-D5F8C91426ACQ34043397-09E8C3FE-02D9-46DD-BE4D-7A8B7780994CQ34060364-782DA04E-20DE-437E-8970-A3EEC13D6130Q34132735-16A73E96-5523-4023-B985-CA04CB7BDC00Q34336023-47B25DE8-9368-4B14-A667-09EDEC09F074Q34404416-FA91CA4B-D094-423A-8941-A3FB11D58F7AQ34613460-E53CF6F1-E9CB-426B-B4C1-065779117A8FQ34722814-EF1B1847-C27E-480A-B4A8-3593BDA56C31Q34757048-5ECAC18D-65DD-4F56-B5F9-CB91BC8D1F89Q34786518-FBC96955-25AE-44CC-9B1A-24B9EF11C222
P2860
Positron-emission tomography and assessment of cancer therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Positron-emission tomography and assessment of cancer therapy.
@ast
Positron-emission tomography and assessment of cancer therapy.
@en
type
label
Positron-emission tomography and assessment of cancer therapy.
@ast
Positron-emission tomography and assessment of cancer therapy.
@en
prefLabel
Positron-emission tomography and assessment of cancer therapy.
@ast
Positron-emission tomography and assessment of cancer therapy.
@en
P356
P1476
Positron-emission tomography and assessment of cancer therapy.
@en
P2093
Bruce D Cheson
Malik E Juweid
P304
P356
10.1056/NEJMRA050276
P407
P577
2006-02-01T00:00:00Z